SUBSCRIBE
Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2005, Vol. 3 ›› Issue (1): 23-27.doi: 10.3736/jcim20050108

• Original Clinical Research • Previous Articles     Next Articles

Therapeutic effect of Xincang Decoction on chronic airway inflammation in children with bronchial asthma in remission stage

Hui-hua Zhu1,Yan-ping Chen1,Jian-er Yu2,Min Wu3,Zhan Li3   

  1. 1. Department of Pediatrics, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
    2. Department of Pediatrics, Shanghai Hospital of Traditional Chinese Medicine, Shanghai, 200071, China
    3. Department of Traditional Chinese Medicine, Xinhua Hospital, Shanghai Second Medical University, Shanghai 200092, China
  • Received:2004-09-22 Online:2005-01-20 Published:2005-01-20
  • Contact: Jian-er Yu E-mail:jianeryu@hotmail.com

RichHTML

1

PDF (PC)

178

Like

Objective

To observe the therapeutic effect of Xincang Decoction on chronic airway inflammation in children with asthma in clinical investigation.

Methods

Xincang Decoction was composed of Flos Magnoliae (Xinyi) and Fructus Xanthii (Cang'erzi), the traditional Chinese herbs for expelling wind. Sixty cases of children with bronchial asthma in remission stage were randomly divided into two groups. Thirty cases in the treatment group were treated with Xincang Decoction and the others in the control group were treated with ketotifen fumarate. The therapeutic effects of the two groups were compared, and the peripheral eosinophil (EOS) count, the levels of immunoglobulin E (IgE), interleukin 4 (IL-4) and interleukin 5 (IL-5), and the pulmonary functions were observed before and three months after the treatment.

Results

After three months treatment, the results showed that the total response rates of the treatment and the control group were 83.3% and 80.0%, respectively, without marked difference (P>0.05). The levels of EOS and IL-5 were obviously decreased after the treatment, and the levels of EOS and IL-5 of the patients in the treatment group were lower than those in the control group (P<0.05). Meanwhile the forced expiratory volume in one second (FEV1) was improved after the treatment, and the FEV1 of the patients in the treatment group was higher than that of the patients in the control group (P<0.05).

Conclusion

Xincang Decoction can decrease the levels of EOS and IL-5 and improve the pulmonary function in treating chronic airway inflammation in children with bronchial asthma in remission stage.

Key words: Asthma,bronchial, Xincang Decoction, Traditional Chinese medical therapy

CLC Number: 

  • R289.5

Tab 1

Comparison of therapeutic effects of 2 groups Cases (%)"

Group n Clinical control Marked effect Effect Failure Total response rate
Treatment 30 6 （20.0%） 11 （36.7%） 8 （26.7%） 5 （16.7%） 25 (83.3%)
Control 30 4 （13.3%） 9 （30.0%） 11 （36.7%） 6 （20.0%） 24 (80.0%)

Tab 2

Comparison of main signs and symptoms integralaverage scores of 2 groups ($\bar{x}$±s)"

Group n Integral average score
Treatment
Before treatment 30 32.83±9.54
After treatment 30 13.87±5.48**
Control
Before treatment 30 32.73±11.54
After treatment 30 9.77±7.19**

Tab 3

Comparison of blood EOS, IgE, IL-4 and IL-5 of 2 groups ($\bar{x}$±s)"

Group n EOS （×109/L） IgE （kU/L） IL-4 （ng/L） IL-5 （ng/L）
Treatment
Before treatment 30 0.95±0.51 108.61±24.04 130.06±67.18 155.07±45.54
After treatment 30 0.38±0.12**△ 61.68±24.20** 108.65±56.58 73.33±23.28**△
Control
Before treatment 30 0.74±0.35 96.66±40.58 118.98±75.90 143.09±35.27
After treatment 30 0.39±0.18** 63.51±32.65** 109.44±70.85 87.67±39.11**

Tab 4

Comparison of pulmonary functions of 2 groups ($\bar{x}$±s)"

Group n FEV1 （L） PEF （L/s） FEF25-75 （L/s）
Treatment
Before treatment 30 1.06±0.42 2.40±0.94 2.15±0.16
After treatment 30 1.50±0.49**△ 3.24±0.96** 2.23±0.63
Control
Before treatment 30 1.35±1.17 2.48±1.08 2.24±0.03
After treatment 30 1.38±0.41 3.07±1.14** 1.95±0.86
[1] 全国儿科哮喘防治协作组. 儿童哮喘防治常规(试行)[J]. 中华儿科杂志, 1998,36(12):747-751
[2] [OTHER].国家中医药管理局.中医病证诊断疗效标准[S]. 南京: 南京大学出版社,1994.66-67.
[3] 郑筱萸 . 中药新药临床研究指导原则(第1版)[M]. 北京: 中国医药科技出版社, 2002,( 第1版):361-390
[4] 于作详 . 刘弼臣教授治疗小儿哮喘的经验[J]. 山西中医, 1998,14(2):6-7
[5] 彭红星 . 陈陶后教授治疗小儿哮喘经验[J]. 山西中医, 1995,11(2):5-6
[6] 张洪春, 葛河明, 晁恩祥 . 支气管哮喘治疗研究进展[J]. 中国医药学报, 1995,20(1):45-46
[7] 胡亚美, 江载芳, 诸福棠 . 实用儿科学(第7版)[M]. 北京: 人民卫生出版社, 2002,( 第7版):631-636
[8] 李明华, 殷凯生, 朱栓立 , 等 .哮喘病学( 第1版)[M]. 北京: 人民卫生出版社,1999,(第1版):45- 50, 157-164
[9] 胡作为, 周燕萍 . 咳喘中医治疗探讨[J]. 甘肃中医学院学报, 2003,20(3):5-8
[10] Busse WW, Calhoun WF, Sedgwick JD , et al. Mechanism of airway inflammation in asthma[J]. Am Rev Respir Dis, 1993,147(6 Pt 2):S20-S24
doi: 10.1164/ajrccm/147.6_Pt_2.S20
[11] Shirakawa T, Li A, Dubowitz M , et al. Association between atopy and variants of the beta subunit of the high-affinity immunoglobulin E receptor[J]. Nat Genet, 1994,7(2):125-129
doi: 10.1038/ng0694-125
[12] Hanifin JM, Schneider LC, Leung DY , et al. Recombinant interferon gamma therapy for atopic dermatitis[J]. J Am Acad Dermatol, 1993,28(2 Pt 1):189-197
doi: 10.1016/0190-9622(93)70026-P
[13] 王文魁, 沈映君 . 辛夷精油的抗炎作用[J]. 陕西中医学院学报, 2000,23(2):40-42
[14] 朱雄伟, 杨晋凯, 胡道伟 . 辛夷成分及其药理应用研究综述[J]. 海峡药学, 2002,14(5):5-7
[15] 戴岳, 毕培曦, 陈耀邦 . 苍耳子对速发型过敏反应的抑制作用[J]. 中国野生植物资源, 2002,21(6):61-64
[1] Yong-ming Zhou, Ming-hui Hu, Jing-ming Yang, Wen-wei Zhu, Zhen-qiao Huang, Shao-hong Zhou, Yi Xu, Jia-hui Lu. Clinical study on idiopathic thrombocytopenic purpura treated with Shengxueling Granule. Journal of Chinese Integrative Medicine, 2004, 2(6): 421-425.
[2] Xiao-yi Zhang, Cheng-bao Kuang. Clinical observation on treatment of nonalcoholic fatty liver disease complicating hyperuricemia by Zhifang Ⅰ Decoction. Journal of Chinese Integrative Medicine, 2004, 2(4): 265-267.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] Jin-rong Fu. Establishment of multivariate diagnosis and treatment system of modern gynecology of traditional Chinese medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 22-24
[2] Hao Li, Ming-jiang Yao, Wen-ming Zhao, Jie Guan, Lin-lin Cai, Ling Cui. A randomized, controlled, double-blind trial of Huannao Yicong capsule in senile patients with mild cognitive impairment. Journal of Chinese Integrative Medicine, 2008, 6(1): 25-31
[3] Zhi-chun Jin. Problems in establishing clinical guideline for integrated traditional Chinese and Western medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 5-8
[4] SUN Ming-yu, ZUO Jian, DUAN Ji-feng, HAN Jun, FAN Shi-ming, ZHANG Wei, ZHU Li-fang, YAO Ming-hui. Antitumor activities of kushen flavonoids in vivo and in vitro. Journal of Chinese Integrative Medicine, 2008, 6(1): 51-59
[5] Min Cheng, Qiong Feng, Shu-wen Qian, Hui Gao, Cui-qing Zhu. Preliminary assay of p-amyloid binding elements in heart-beneficial recipe. Journal of Chinese Integrative Medicine, 2008, 6(1): 68-72
[6] Ning-qun Wang, Liang-duo Jiang, Zong-xing Li. Research progress in asthma-related quality of life. Journal of Chinese Integrative Medicine, 2008, 6(1): 93-97
[7] Jing-yuan Mao, Chang-xiao Liu, Heng-he Wang, Guang-li Wei , Zhen-peng Zhang, Jie Xing, Wang Xian liang , Ying-fei Bi . Effects of Shenmai Injection on serum concentration and pharmacokinetics of digoxin in dogs with heart failure. Journal of Chinese Integrative Medicine, 2010, 8(11): 1070-1074
[8] Zhi-mei Wang, Bin Zhang. A study on translation of ellipses in Huangdi Neijing from perspective of hermeneutic theory. Journal of Chinese Integrative Medicine, 2010, 8(11): 1097-1100
[9] Gui Yu, Jie Wang. Thinking on building the network cardiovasology of Chinese medicine. Journal of Chinese Integrative Medicine, 2012, 10(11): 1206-1210
[10] Pedro Saganha João, Doenitz Christoph, Greten Tobias, Efferth Thomas, J. Greten Henry. Qigong therapy for physiotherapists suffering from burnout: a preliminary study. Journal of Chinese Integrative Medicine, 2012, 10(11): 1233-1239
Journal of Integrative Medicine, ISSN: 2095-4964 CN 31-2083/R
Copyright © Journal of Integrative Medicine
Powered by Beijing Magtech Co. Ltd
沪公网安备31010602003416号      沪ICP备18017633号-3